Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired ...

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and ...

Corona Remedies introduces affordable generic version of empagliflozin for type 2 diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:50 Hrs [IST] Corona Remedies Limited ha ...

Continuing our series highlighting recent presentations from Nursing in Practice 365 events, diabetes specialist midwife ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

Medium and high T2DM genetic risk not linked to increased risk for ASCVD when TV viewing is no more than one hour/day. (HealthDay News) — Medium and high type 2 diabetes (T2D) genetic risks are ...

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its ...

The continued global increase in the prevalence of type 2 diabetes mellitus (T2DM) poses a significant challenge to the health of individuals, societies, and nations. According to the 10th edition ...

In the MediPlus database, 43,486 patients had a diagnosis of type 2 diabetes. Of the 11,543 who had their first observed diagnosis between 2003 and 2005, 9,158 patients (54% male) met the ...